Abstract: In some embodiments of the present disclosure, a sustained release osmotic-controlled pharmaceutical composition is provided, including: a core and a semi-permeable membrane coated on the core. The core includes a drug compartment, in which the drug compartment includes a first active ingredient, a first polymer and a first osmogen, and the first active ingredient includes lurasidone, a pharmaceutical acceptable salt of the lurasidone or a combination thereof. The semi-permeable membrane includes a membrane body and at least one pore distributed in the membrane body.

Abstract: A method and system for providing access to a resource. A request for an individual within an organization to access the resource is received. In response to the request having been received, at least one constraint for accessing the resource by the individual is ascertained, based on respective constraints for accessing the resource by one or more other individuals in the organization. The one or more other individuals have a same role in the organization as the individual or have a respective relationship with the individual. The at least one constraint is provided to the individual.

Abstract: The present invention relates to an anti-TNFR2 antibody, a preparation method therefor, a composition thereof, and use thereof. The present invention also provides a method for treating a TNFR2-associated disease and/or disorder, such as cancer.

Abstract: A pharmaceutical composition is provided. The pharmaceutical composition comprises an active pharmaceutical ingredient (API), a polymer and a solvent. The API comprises cariprazine, a pharmaceutically acceptable salt of cariprazine, or a mixture thereof. The polymer comprises poly(lactic acid) (PLA), poly(lactide-co-glycolide) (PLGA), poly(glycolic acid) (PGA), or a combination thereof. A method for preparing the pharmaceutical composition is also provided.

Abstract: The present invention relates to novel antibodies or antigen-binding fragments thereof that specifically bind to CD73 and compositions comprising the antibodies or antigen-binding fragments thereof. The present invention also relates to a nucleic acid encoding the antibody or antigen-binding fragment thereof of the present invention, a vector comprising the polynucleotide, a host cell comprising the nucleic acid or the vector, an immunoconjugate and pharmaceutical composition comprising the antibody or antigen-binding fragment thereof. Furthermore, the present invention relates to the uses of these antibodies or antigen-binding fragments thereof in the immunotherapy, prevention and/or diagnosis of diseases.

Abstract: Disclosed herein is an injectable depot formulation and use thereof for treating a mental disorder. The injectable depot formulation comprises cariprazine free base particles and a pharmaceutically acceptable carrier. The cariprazine free base particles have a median particle size by volume (Dv50) ranging from 0.5 ?m to 100 ?m.

Abstract: A method for acquiring a flight path is provided. The method for acquiring a flight path includes: acquiring a flight path acquisition request of a target aircraft, where the flight path acquisition request includes a starting location and a destination location of the target aircraft; acquiring one or more reference flight pipes based on the starting location and the destination location, where each reference flight pipe corresponds to pipe attribute information; determining occupancy information of the reference flight pipes by other aircrafts; and determining a target flight pipe from the reference flight pipes according to the pipe attribute information and the occupancy information, and acquiring a target flight path of the target aircraft based on the target flight pipe.

Abstract: A method for realizing reuse among software development tasks is provided. The method includes receiving information data of a completed software development task, and generating a first identification corresponding to the software development task. The method includes receiving program code corresponding to the completed software development task and the first identification, and generating one or more second identifications of the program code.

Abstract: A cloud virtual server scheduling method includes creating a cloud virtual server cluster including a first preset number of virtual servers; initializing the first preset number of virtual servers included in the cloud virtual server cluster; and receiving a user request to use n number of virtual servers. The method also includes, based on the user request, determining whether the cloud virtual server cluster includes at least n number of virtual servers in an idle state. Further, the method includes, when the cloud virtual server cluster includes at least n number of virtual servers in the idle state, scheduling n number of virtual servers in the idle state to fulfill the user request and, when the cloud virtual server cluster does not include at least n number of virtual servers in the idle state, creating and initializing n number of virtual servers and scheduling the n number of virtual servers to fulfill the user request.

Abstract: A method for realizing reuse among software development tasks is provided. The method includes receiving information data of a completed software development task, and generating a first identification corresponding to the software development task. The method includes receiving program code corresponding to the completed software development task and the first identification, and generating one or more second identifications of the program code.

Abstract: A cloud-based data backup and operation method is provided. The method includes obtaining system version information of an operating system used on a mobile terminal; based on the system version information of the operating system on the mobile terminal, creating a mirror system same as the operating system used on the mobile terminal on a virtual server in a cloud; and synchronizing data of the mobile terminal itself to the mirror system on the virtual server to form backup data.

Abstract: The invention develops a developed a thermosensitive injectable hydrogel based on HA and a copolymer of polyethylene oxide (PEO) and polypropylene oxide (PPO), which has a gel formation temperature from 30° C. to 37° C. The thermosensitive injectable hydrogel of the invention provides a potential drug delivery system that can increase therapeutic efficacy of the drug.

Abstract: The invention develops a developed a thermosensitive injectable hydrogel based on HA and a copolymer of polyethylene oxide (PEO) and polypropylene oxide (PPO), which has a gel formation temperature from 30° C. to 37° C. The thermosensitive injectable hydrogel of the invention provides a potential drug delivery system that can increase therapeutic efficacy of the drug.

Abstract: An iconic network within a computer system is displayed on a display device. Multithreading execution of the iconic network is performed. The computer system receives user input to group icons of the iconic network into separate thread graphical blocks displayed on the display device. The computer system assigns the thread graphical blocks to separate threads of the operating system. The computer system executes the icons grouped in the separate thread graphical blocks by executing the separate threads of the operating system. Data associated with the icons of the iconic network is exchanged between the computer system and external electronic instruments through an instrument bus as the iconic network is processed.